ClinicalTrials.gg
Not yet recruitingNCT07858188Updated Oct 5, 2026

Study on the Effect of Electronic Moxibustion on Non-Specific Low Back Pain in Young Adults

An interventional study of Electronic Moxibustion and ibuprofen or celecoxib analgesics in Electronic Moxibustion, Low Back Pain and Muscle Hardness, sponsored by Nanfang Hospital, Southern Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Nanfang Hospital, Southern Medical University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Low Back Pain with a site in China — 17 open to participants now, 19 under way, none of them phase 3. Low Back Pain · China.

Planned enrollment
17th of 42
90 · median 84
Started
2026
with 7 others
No phase
36 of 49
14 open now
Primary completion
2027-09
later than 12 of 18 live
Registered
47th of 49
by date

Among the 49 studies in Low Back Pain with a site in China, this one is the 17th largest by planned enrollment of the 42 interventional ones that give a count, is one of 8 that started in 2026, is one of 36 with no phase, reaches primary completion later than 12 of the 18 other live ones, and was the 47th registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

17 of the 49 studies in Low Back Pain with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Low Back Pain with a site in China, or all of them as a file.
02

Study summary

This is an interventional clinical study. A total of 90 subjects aged 18 to 40 years are planned to be recruited. The subjects have low back pain that affects daily work and life, resulting in reduced exercise tolerance or aggravated pain after exercise, while retaining basic living ability and being capable of performing partial activities; their VAS scores range from 4 to 6. At baseline, the duration of subjects' low back pain and disability index will be recorded, along with muscle stiffness and electroencephalogram findings. Afterwards, electronic moxibustion treatment will be administered for 4 weeks. Subjects will be randomly divided into a treatment group and a control group with equal numbers of participants. The treatment group will use a Wenyang instrument with a rated frequency of 50 Hz, with the temperature set between 40℃ and 60℃ based on subjects' comfort level. Each treatment session lasts 30 to 60 minutes, 5 times per week for 4 weeks. The Wenyang instrument is used by subjects at home, with researchers providing remote guidance and supervision via voice or video. Subjects will check in and upload records after each use of electronic moxibustion, which will be documented by researchers. If subjects suffer from unbearable low back pain during the study, they may take oral ibuprofen or celecoxib for pain relief. The dosage and administration time will be recorded, and check-in and upload will be completed after each dose of analgesics for researchers' documentation. Subjects in the control group will take oral ibuprofen or celecoxib for pain relief as needed (i.e., when they feel pain). The dosage and administration time will be recorded with check-in and upload. After 4 weeks of intervention, the two groups will be compared in terms of the number of days of analgesic use or total consumed dosage, as well as changes in VAS scores, disability index, muscle stiffness and electroencephalogram findings.

Read the detailed description

This is an interventional clinical study. A total of 90 subjects aged 18 to 40 years are planned to be recruited. The subjects have low back pain that affects daily work and life, resulting in reduced exercise tolerance or aggravated pain after exercise, while retaining basic living ability and being capable of performing partial activities; their VAS scores range from 4 to 6. At baseline, the duration of subjects' low back pain and disability index will be recorded, along with muscle stiffness and electroencephalogram findings. Afterwards, electronic moxibustion treatment will be administered for 4 weeks. Subjects will be randomly divided into a treatment group and a control group with equal numbers of participants. The treatment group will use a Wenyang instrument with a rated frequency of 50 Hz, with the temperature set between 40℃ and 60℃ based on subjects' comfort level. Each treatment session lasts 30 to 60 minutes, 5 times per week for 4 weeks. The Wenyang instrument is used by subjects at home, with researchers providing remote guidance and supervision via voice or video. Subjects will check in and upload records after each use of electronic moxibustion, which will be documented by researchers. If subjects suffer from unbearable low back pain during the study, they may take oral ibuprofen or celecoxib for pain relief. The dosage and administration time will be recorded, and check-in and upload will be completed after each dose of analgesics for researchers' documentation. Subjects in the control group will take oral ibuprofen or celecoxib for pain relief as needed (i.e., when they feel pain). The dosage and administration time will be recorded with check-in and upload. After 4 weeks of intervention, the two groups will be compared in terms of the number of days of analgesic use or total consumed dosage, as well as changes in VAS scores, disability index, muscle stiffness and electroencephalogram findings.

03

Conditions studied

  • Electronic Moxibustion
  • Low Back Pain
  • Muscle Hardness

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Agree to participate in the study and voluntarily sign the form;
  • Typically developing young adults aged 18-40 years of any gender, with a VAS score between 4 and 6 inclusive;
  • Symptoms include low back pain aggravated by cold, difficulty turning, dark tongue with white greasy coating (cold-dampness and blood stasis pattern); stabbing pain with fixed location, tenderness on pressure, worse at night and milder in the daytime (blood stasis low back pain); dull lingering low back pain with soreness and weakness, persistent symptoms, local cold sensation, preference for warmth and pressure, worsening upon cold exposure, cold limbs (kidney-yang deficiency low back pain);
  • No history of spinal surgery, nerve root compression or severe organic diseases.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, broken skin or abnormal temperature sensation;
  • Organic diseases such as lumbar disc herniation, fractures and tumors;
  • Received acupuncture, tuina or analgesic treatment within the past month;
  • Combined with mental illness or brain injury (affecting EEG);
  • Considered unsuitable for participation in this study as judged by the researchers.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Electronic Moxibustion Group

    The experimental group used a Yang-warming instrument with a rated frequency of 50 Hz. The temperature was set at 40-60 °C, adjusted mainly according to the subject's comfort level. Each treatment lasted 30-60 minutes, with 5 sessions per week for 4 consecutive weeks. Subjects used the Yang-warming instrument at home, and researchers provided remote guidance and supervision via voice or video calls. Subjects checked in and uploaded records after each session of electronic moxibustion, which were documented by researchers. If subjects experienced unbearable lumbago during the study, they could take oral ibuprofen or celecoxib for pain relief. The dosage and time of medication were recorded, and check-in records were uploaded after each painkiller administration for researchers' documentation.

    Other: Electronic Moxibustion

  • Active comparator
    control group

    In the control group, subjects took oral ibuprofen or celecoxib analgesics at an unspecified time (i.e., when the subjects felt pain). The dosage and time of medication were recorded and uploaded via check-in.

    Drug: ibuprofen or celecoxib analgesics

Interventions

  • OtherElectronic Moxibustion

    The subjects were equally divided into the experimental group and the control group. The experimental group received electronic moxibustion 5 times a week for 4 weeks, used painkillers when experiencing subjective pain, and uploaded check-in records.

  • Drugibuprofen or celecoxib analgesics

    The control group took oral painkillers when experiencing subjective pain and uploaded check-in records.

06

What researchers measure

Primary outcomes

  1. Drug dosage

    Total consumption of painkillers during the two groups of trials (within four weeks).

    Time frame: Starting from the measurement baseline until the end of the 4-week intervention period, the difference in medication dosage used by the two groups during the intervention will be evaluated.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual-participant data will not be shared publicly due to participant privacy protection requirements, and the informed consent does not include provisions for open data sharing.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 12 months is close to that.

Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2026
First posted
Oct 5, 2026
StartEst.
Sep 2026
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07858188
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

chao chen, Doctoral degree
Contact
nfyyec@163.com
+86-20-6278723

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion